What price for Big Pharma M&A in the supplements business?

Drugmakers are turning to vitamins for a shot of consumer health growth, and a host of supplement makers are prime targets. But with consumer product companies vying for the same buyouts, prices could be steep. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.